Brief: Vistagen And Fuji Enter Exclusive Negotiation Agreement For A Potential License To Develop And Commercialize Vistagen’S Investigational Menopausal Hot Flash Therapy, Ph80 Nasal Spray, In Japan

Fuji Pharma

05/09/2023 14:02

Fuji Pharma Co Ltd  4554.T :
    * VISTAGEN AND FUJI ENTER EXCLUSIVE NEGOTIATION AGREEMENT
FOR A
POTENTIAL LICENSE TO DEVELOP AND COMMERCIALIZE VISTAGEN’S
INVESTIGATIONAL MENOPAUSAL HOT FLASH THERAPY, PH80 NASAL SPRAY,
IN JAPAN
    * VISTAGEN THERAPEUTICS INC- VISTAGEN TO RECEIVE $1.5
MILLION AND
FUJI TO OBTAIN TIME-LIMITED EXCLUSIVE NEGOTIATION PERIOD FOR
JAPANESE MARKET

Source text for Eikon:  ID:nBw3dQdqLa 
Further company coverage:  4554.T